Philanthropic Leaders Catalyzing Innovation at Hoag
Mission Hoag Innovators is a group of donors with a shared vision for advancing health care innovation at Hoag by leveraging the power of collective giving. The group is defined by its active engagement, discretionary review and collaborative decision-making on which philanthropic investments will provide the greatest impact.
TABLE OF CONTENTS
Letter From The Founders
7
Impact
8
Financials
10
I Am A Hoag Innovator
12
Project Investment Updates
18
Innovation In Their Words
35
When we evaluated our philanthropic commitment to Hoag, we envisioned a platform for us and other like-minded donors to support multiple initiatives while learning and growing along the way. We are excited about how this dynamic group of donors is helping Hoag drive health care innovation here in our community and beyond. As we look to further our impact, we hope you will join us in inviting others to become Hoag Innovators. Robert and Kitty Brunswick Founding Hoag Innovators
Dear Hoag Innovators, Health care has seen an extraordinary rise in innovation in recent years. While technology is certainly a key driver, being a true health care innovator extends far beyond technological advancements. Today’s health care innovators possess a relentless drive to reimagine and reinvent how care can be delivered more effectively, affordably and efficiently. They operate with the boldness to take risks, seize opportunities and engage in powerful collaborations that can transform the patient experience and improve health outcomes. Hoag embodies this broader definition of health care innovation, and it requires significant resources. That is why our role as Hoag Innovators is an important one. We are philanthropic investors,
LETTER FROM THE FOUNDERS
advisors and community influencers acting together to ensure Hoag is positioned to pursue innovation at every turn. The 13 projects we have funded to date, detailed in this edition of our annual Hoag Innovators Impact Report, exemplify Hoag’s commitment to innovation across the enterprise. Through engaged philanthropy and collaborative decision-making, we are helping Hoag emerge as a destination where the future of health care is designed, launched and implemented. With your continued support, the possibilities are endless. Thank you for your generosity and for being part of Hoag Innovators. Sincerely, Robert and Kitty Brunswick Founding Hoag Innovators
IMPACT Now in its fourth year of philanthropic investment, Hoag Innovators continues to make a significant impact on Hoag and its innovation strategy. Hoag Innovators have collectively invested in groundbreaking projects that represent extraordinary gains in health care across a wide range of medical specialties and transform the patient and provider experience. These advances simply would not be possible without Hoag Innovators’ philanthropy. As a result, Hoag is better equipped to not only stay at the forefront of health care innovation but lead the way.
HOAG INNOVATORS | IMPACT REPORT
IMPACT
Total Giving by Calendar Year MILLION
7
$6,580,000*
6 $5,384,000*
5
4
3
$1,926,773
2 $1,207,663
$1,500,000
$1,228,832**
1
0 2017
2018
2019
2020
2021
2022
*Total includes funds provided by the Lori and Mike Gray matching gift challenge **Donations as of November 1, 2022
9
Fund Allocation & Distribution Across Hoag
5%
Women’s Health Institute $175,000
42%
Hoag Family Cancer Institute $1,400,000
8%
Radiology & Imaging $250,000
8%
Jeffrey M. Carlton Heart & Vascular Institute $250,000
9%
FINANCIALS
Infection Prevention $305,000
HOAG INNOVATORS | IMPACT REPORT
10% Pickup Family Neurosciences Institute $325,000
18%
Hoag-Wide Initiatives $600,000
FINANCIALS
Total Body Photography: VECTRA WB360 Whole Body 3D Imaging
NK Cell Therapy Program
$500,000
$400,000
Hoag at Home
Biocartis Idylla™ Technology Platform
$350,000
$150k
Transitional Care Pilot Program
$500,000 Clinical Pilot of Cognivue
Cancer Early Detection Analysis Lab
$100k
Invenio NIO Laser Imaging
$200,000
$125k
Xenex Germ-Zapping™ Robots (COVID-19 Support)
$180,000
$125k
LEAF Device System Implementation in Critical Care Units
Marfan Syndrome & Related Conditions Program
$250,000 Center for Artificial Intelligence and Advanced Imaging at Hoag = AI²
$250,000 Hoag Pacify App
Giving by Fund
$175,000
Hoag Innovators Fund
$8,385,268
Hoag Innovators Endowment Fund
$9,442,000
11
HOAG INNOVATORS | IMPACT REPORT
I AM A HOAG INNOVATOR
Since it was founded in 2017, Hoag Innovators’ unique model of philanthropy has attracted over 50 families and individual members and continues to grow. While Innovators come to the group with a wide range of backgrounds and reasons for giving to Hoag, all are committed to advancing innovation in health care through collaborative decision-making and engaged philanthropy.
13
Hoag Innovators share what inspired them to get involved and why their experience is personally meaningful.
Innovation is changing patient care and outcomes. That’s why I’m so excited about what I’m learning through Hoag Innovators. Richard Wolpow Member since 2021
After spending 21 days at Hoag for a ruptured aorta, Richard Wolpow was considering how he could say thank you for the excellent care he received. In addition to making a generous gift in support of the Jeffrey M. Carlton Heart & Vascular Institute, Richard felt compelled to also make a gift to join Hoag Innovators as a way of expressing his gratitude to Hoag and getting more involved in the organization that made a deep impact on him. For Richard, an entrepreneur with experience in the health care industry, being part of Hoag Innovators has provided an inside look into how Hoag is leveraging innovation to build a first-in-class organization that serves the entire community. “Hoag is very forward-thinking,” says Richard, “and through innovation, Hoag is creating its own uniqueness and recognition within the marketplace and our region. It benefits all of us.”
HOAG INNOVATORS | IMPACT REPORT
I AM A HOAG INNOVATOR
The money we invest today through Hoag Innovators will have a payoff in the future. Innovation can make the impossible possible. Andria Strelow Member since 2021
Peter Strelow has been in the investment business for more than 20 years, and he and his wife, Andria, bring the spirit of investing to their philanthropic work. The Strelows give with the conviction that funds invested in the right way today will yield positive impact in the future. “It may not be tomorrow or even this year, but supporting innovation that can generate significant medical advances will pay off over a long period,” says Andria. The Strelows have lived in Newport Beach for over a decade and have long trusted Hoag with their family’s health. Beyond that, Hoag’s dedication to the health of the community along with the institution’s high level of professionalism have motivated the Strelows to invest philanthropically. When the Strelows were introduced to Hoag Innovators, they knew it would be a meaningful way to support Hoag. As members, they appreciate the opportunity to see the results of their giving come to fruition and enjoy the camaraderie with other Hoag Innovators who share the same commitment to improving health care innovation in our community.
15
Through Hoag Innovators, you’re on the ground floor of some of the most exciting health care advancements. Otis Healy Member since 2021
A loyal and longtime Hoag donor and volunteer, Otis Healy was excited about the opportunity to expand his impact on the organization through participation in Hoag Innovators. To Otis, Hoag Innovators offers the chance to be among the first to learn about some of the recent and imaginative solutions in health care presented by physicians who are on the forefront of a particular area. “It can be difficult to decide which projects to allocate funding to,” says Otis, “but it is exciting to hear all of the doctors make their pitches and learn about the breakthroughs they are working on.” An experienced philanthropist, Otis appreciates the different approach to giving Hoag Innovators offers, including the ability to regularly come together with like-minded individuals who share a common goal. “Not only are we able to be part of many groundbreaking medical advancements through our support, we learn a lot in the process—both from the physicians and from each other. It’s very valuable.”
HOAG INNOVATORS | IMPACT REPORT
I AM A HOAG INNOVATOR
Lori and I believe Hoag Innovators is a game changer! Hoag Innovators shows the impact a well-executed, really good idea can have. It is clear when you add engaged philanthropy to the mix, you have a recipe for something very special. When we decided to support the Brunswick’s vision with a matching endowment, I don’t think anyone thought we would reach 94% of the $10 million goal so quickly. What stands out: Hoag Innovators has a bright future. Mike Gray
The Hoag Innovators Endowment Fund was established in 2020 to ensure Hoag’s ability to remain a leader in health care innovation in perpetuity. Launched with a generous matching gift of up to $5 million from visionary donors Lori and Mike Gray, the endowment currently totals $9.4 million of its $10 million goal.
17
PROJECT INVESTMENT UPDATES HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
People & Programs Hoag at Home High-Quality Health Care Brought to Your Doorstep
INVESTMENT DATE
Fall 2021 INVESTMENT AMOUNT
$500,000 THE CHALLENGE Patients often recover faster from injury or surgery at home, surrounded by family in the comfort of a familiar environment. Acute, at-home medical services personalized to each patient that span prevention, diagnostics, treatment and recovery will help meet the anticipated needs of Orange County’s aging population. THE INNOVATION Hoag at Home is a comprehensive home care service offering that provides patients with the high-quality personalized care they need in the comfort of their home. Through Hoag at Home, medical and support services are brought to the patient, and each patient receives an individual care plan to meet their specific goals and needs. The Hoag Innovators’ investment will support the latest monitoring technology and establish a command center to manage patients remotely. THE RESULTS The Hoag at Home team has evaluated Hoag’s patient census and developed pro formas around more than 250 diagnoses that will drive the Hoag at Home patient census and eventual expansion. Two outside consulting firms with expertise in acute home health care vetted the pro formas. Both firms have submitted proposals for technology, consulting and education. The Hoag at Home team is deliberating on the best partnership for Hoag.
19
NK Cell Therapy Program
INVESTMENT DATE
Fall 2020 INVESTMENT AMOUNT
Revolutionizing Pancreatic Cancer Treatment
$500,000 THE CHALLENGE
60 patients
consented and 51 patients treated in the trial at HFCI to date
Up to 400 Hoag patients
with pancreatic cancer annually could receive this advanced treatment when trial moves to phase III NK cells are significantly safer, faster, less toxic and less expensive than traditional CAR T-cell immunotherapy Patients in our community diagnosed with pancreatic cancer can access the most advanced care without being hospitalized or leaving Orange County
HOAG INNOVATORS | IMPACT REPORT
Considered one of the deadliest cancers, pancreatic cancer is one of the few cancers for which there has not been substantial treatment advancements. Currently, only 9% of individuals diagnosed survive for five years or longer. The median survival prognosis is five to eight months. Pancreatic cancer is estimated to become the second-leading cause of cancer death by 2030. Effective therapy for pancreatic cancer is needed. THE INNOVATION The Hoag Family Cancer Institute (HFCI) is one of only two sites in the country to offer the most advanced immunotherapy clinical trial currently available for the treatment of locally advanced and metastatic pancreatic cancer. In partnership with leading immunotherapy company ImmunityBio, the phase II trial uses innovative NK (natural killer) cells, which are manipulated to recognize and target cancer cells. When injected into the patient, the NK cells activate the patient’s immune system to create antibodies that fight cancer in combination with chemotherapy. THE RESULTS With promising early results, the therapy has the potential to change the standard of care for pancreatic cancer. The trial not only brings hope to patients receiving this devastating diagnosis, it advances Hoag’s reputation as a destination site for cancer immunotherapy.
PROJECT INVESTMENT UPDATES
Marfan Syndrome & Related Conditions Program Expert Care Locally for Patients with Rare Disease
INVESTMENT DATE
Spring 2019 INVESTMENT AMOUNT
$250,000 THE CHALLENGE Marfan syndrome and related conditions are rare and life-threatening genetic disorders that put patients at risk for aortic disease and dissection. Few programs exist in the U.S., so many patients must travel for expert care. THE INNOVATION
Because of your donations, Hoag is at the forefront of these rare diseases, hosting events and national conferences and being a clinical site for groundbreaking new research. I now have the opportunity to potentially receive a lifesaving drug at Hoag with a clinical trial. What was once an impossibility is now a reality. Thank you, Hoag Innovators, for providing the foundation for a brighter, healthier and longer future for me, my family and other families like mine. Kaitlin Hoag Vascular Ehlers-Danlos (vEDS) Patient
World-renowned cardiologist Dr. David Liang, who was recruited from Stanford thanks in part to the investment provided by Hoag Innovators, leads Hoag’s multidisciplinary team of experts at Hoag’s comprehensive Marfan Syndrome & Related Conditions Program. The only comprehensive Marfan syndrome program in Southern California, it’s also the only one at a community hospital in the United States. THE RESULTS •
74 patients with confirmed connective tissue disorders
•
55 families cared for
•
327 genetic evaluations completed
•
Selected as one of three sites in CA for the Aytu BioPharma drug study for vascular Ehlers-Danlos patients
•
Only hospital in California outside of Stanford to have a Marfan Foundation Professional Advisory Board member on staff
•
Where patients travel from: Northern California, Inland Empire, San Diego County, Los Angeles, Washington State, Utah, Texas, Massachusetts
•
National recognition of Hoag’s program – In the summer of 2022, Hoag hosted the Marfan Foundation’s Annual Conference, a first for a nonacademic institution. It was the first time the Marfan community has gathered in person since COVID-19. Hoag also hosted the 2022 Southern California Marfan Foundation Walk for Victory.
21
Technology and Equipment Total Body Photography: VECTRA WB360 Whole Body 3D Imaging Improving Skin Cancer Early Detection
INVESTMENT DATE
Spring 2022 INVESTMENT AMOUNT
$400,000 THE CHALLENGE Melanoma is the deadliest form of skin cancer, and Southern California has one of the highest incidences of the disease in the world. Implementing better methods of early detection, especially for those at increased risk of developing melanoma and other skin cancers, can save lives. THE INNOVATION The VECTRA WB360 whole body 3D imaging uses 46 cameras that spontaneously fire to capture 3D total body images, allowing patients to have all their moles and lesions mapped out in less than two seconds. The technology allows clinicians to track changing lesions, identify those of concern and detect melanoma and other skin cancers sooner than with traditional detection methods. The technology not only reduces the number of unnecessary biopsies, it also fundamentally changes the way dermatologists deliver care to high-risk patients with a history of skin cancer. Thanks to the support of Hoag Innovators, Hoag will be the first institution in California to adopt VECTRA WB360 whole body 3D imaging, joining the ranks of Memorial Sloan Kettering Cancer Center and Johns Hopkins Medicine. THE RESULTS Installation of the VECTRA WB360 whole body 3D imaging system is slated for early 2023. Hoag received a $200,000 research grant aimed at improving the imaging system’s AI algorithm to help physicians detect skin cancer.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Clinical Pilot of Cognitive Screening in Acute Care Settings: Cognivue Setting the Standard for Cognitive Health Assessments
400 patients
have received neurological assessments with Cognivue through the clinical pilot to date
INVESTMENT DATE
Spring 2022 INVESTMENT AMOUNT
$200,000 THE CHALLENGE There is no current standard of care for assessing cognitive health within the U.S. In addition to increased age, a number of medical conditions, diseases and health episodes can cause cognitive decline. Identifying changes in cognitive function at the earliest possible time will help ensure appropriate triage and diagnosis, ultimately leading the patient to the right treatment plan sooner. THE INNOVATION Cognivue is the first FDA-cleared technology for self-administered computerized cognitive assessment. Test results are provided for six cognitive domains, including visual perception, attention, language, memory, delayed recall and abstraction. With Hoag Innovators’ funding, Hoag will be the first in Southern California to implement Cognivue to conduct routine cognitive function screenings across a broad range of neurological disorders. THE RESULTS •
Cognivue devices have been deployed in Hoag’s Epilepsy Monitoring Unit and outpatient Neuropsychological Assessment Clinic
•
400 patients have received neurological assessments with Cognivue through the clinical pilot to date
•
Cognivue devices and assessments will soon be implemented in Hoag’s newly launched Center for Integrative Brain Health, Hoag Medical Group primary care physician offices and outpatient neurological clinics
23
Biocartis Idylla™ Technology Platform for Molecular Diagnostics Testing and Translational Pathology Increasing the Speed of Cancer Diagnosis
Results of molecular testing on a singular gene molecular profile for Hoag patients will be available in
24 hours instead of 10 days
INVESTMENT DATE
Spring 2021 INVESTMENT AMOUNT
$150,000 THE CHALLENGE Every patient’s cancer is unique. Through the molecular testing of tumors, gene abnormalities or mutations causing a patient’s cancer can be identified, which is the key to unlocking the treatment that will be most effective. Performing molecular testing in-house instead of using an outside laboratory can save precious time when it comes to diagnosis and initiation of a targeted treatment plan while decreasing cost. THE INNOVATION The Biocartis Idylla™ technology platform is a fully automated, real-time molecular testing system for in-house molecular testing for cancer patients to guide targeted, personalized treatment decisions. THE RESULTS Hoag recently received the Biocartis Idylla™ equipment, and setup, development of standard operating procedures and fulfillment of regulatory requirements for use of the technology are in process. Select Hoag Family Cancer Institute staff will soon undergo technical training led by the vendor. Hoag’s Precision Medicine team is also validating the assay test for lung cancer (EGFR testing). Once the technology is fully implemented, results of molecular testing on a singular gene molecular profile for Hoag patients will be available in 24 hours instead of 10 days. The results will indicate if a current treatment protocol would be effective for that patient, allowing some patients to quickly start on their treatment while minimizing negative side effects of non-effective treatments for patients with a more complex diagnosis.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Center for Artificial Intelligence and Advanced Imaging at Hoag = AI² Harnessing the Power of AI to Improve Imaging
INVESTMENT DATE
Spring 2021 INVESTMENT AMOUNT
$250,000 THE CHALLENGE Recent substantial advances in artificial intelligence (AI) accuracy have created new possibilities to integrate the technology into the practice of radiology. Harnessing the power of AI will allow Hoag Radiology to capture, review and interpret those images which are critical to successful diagnosis and treatment at the highest level of patient comfort, with an improved rate of accuracy and greater bandwidth for serving more patients in less time. THE INNOVATION Leading AI-based software, Aidoc, will increase Hoag Radiology’s speed, efficiency and improve accuracy by performing double reads in the image screening process. Additionally, Aidoc offers “Team Notification” tools, which can be used to emergently notify the appropriate care team when acute, emergent pathology is identified and intervention is needed immediately. This can save precious minutes of coordination time by notifying each care provider simultaneously with the touch of a button and sending the images directly to their phones. THE RESULTS Following contract negotiations, cyber security arrangements and hardware procurement, Hoag Radiology will launch a 60-day trial period of Aidoc and evaluate the results before permanently integrating the software.
25
Cancer Early Detection Analysis Lab Identifying Cancer Recurrence Sooner
INVESTMENT DATE
Spring 2021 INVESTMENT AMOUNT
$350,000 THE CHALLENGE Using innovative applied genomics technology, physicians can develop a personalized, non-invasive approach to each cancer survivor’s posttreatment surveillance. Cancer recurrence is a significant risk for many cancer survivors, and this new technology can help physicians detect cancer recurrence at the earliest possible stage, offering the best chance at successful treatment. Providing physicians with timely data can also indicate conventional treatments are not working, allowing for immediate treatment revisions and alterations. THE INNOVATION Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) provides analysis of the protein content of exosomes, small vesicles produced by cancer cells that contain DNA, RNA, microRNA, lipids and proteins. Hoag’s Precision Medicine team will use this new technology in a clinical research study to develop personalized protein signatures to create biomarkers by analyzing patient blood and/or urine samples. Samples will be obtained prior to, during and after cancer surgery and treatment, providing a longitudinal set over the course of their disease. These real-time samples will identify protein increases or spikes in patients, indicating cancer recurrence or growth sooner than traditional methods. THE RESULTS The Hoag Precision Medicine team developed the protocol for the Individual Biomarker Development in Patients Treated for Cancer Study and received regulatory approval from the Western Institutional Review Board. Lab equipment has been ordered. The Hoag Precision Medicine team will undergo training from Biological Dynamics, Inc. and Bruker, the vendors for the exosome isolation instrument and laser, respectively, on the use of the equipment and technology. To date, five patients have been enrolled in the study and preoperative levels obtained.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Xenex GermZapping™ Robots Exceeding Infection Prevention Standards
INVESTMENT DATE
Spring 2020 (Reallocation from Bioquell ProteQ Bio-Decontamination System) INVESTMENT AMOUNT
$180,000 THE CHALLENGE Hoag’s commitment to infection prevention and patient safety drives the organization’s continuous search for innovative ways to enhance the hospital’s cleaning and disinfecting processes, which became more important than ever with the onset of the COVID-19 pandemic. THE INNOVATION Xenex Germ-Zapping™ Robots provide an additional layer of protection against the bacteria and germs that can lead to health care-associated infections and surgical site infections. The robots use UV technology to disinfect the area without causing damage to hospital surfaces and are used following Hoag’s rigorous manual cleaning process by our environmental services team. THE RESULTS •
Phase I has been fully implemented: three robots deployed for weekly use in Hoag Hospital Newport Beach’s 21 operating rooms and daily use at Hoag Hospital Irvine’s two operating rooms. It takes 30 minutes to disinfect one operating room with the robot
•
Phase II is now in process: Expanded use of the robots to include terminally cleaning patient rooms with Candida auris, or C. auris, a highly resistant fungus that has been causing outbreaks in Orange County. C. diff isolation rooms will be targeted next
•
Hoag’s use of the Xenex Germ-Zapping™ Robots increases the confidence of patients, the community and hospital staff that Hoag is making every effort to ensure the highest levels of safety
27
Hoag Pacify App Supporting Healthy Moms and Babies
INVESTMENT DATE
Fall 2019 INVESTMENT AMOUNT
$175,000 THE CHALLENGE
“Thank goodness for this app and all the wonderful lactation consultants. My breastfeeding journey is going another day because I can call and get the support I need right away. Thank you!” Katie Hoag Patient and Pacify App User
“The lactation consultant was so supportive and encouraging in this tough process for a new mom.” Jothi Hoag Patient and Pacify App User
HOAG INNOVATORS | IMPACT REPORT
During the early days of a newborn baby’s life, parents need fast answers and resources they can trust. Providing virtual and convenient support to mothers and their babies can help make the transition from the delivery room to the home environment smoother. THE INNOVATION The Hoag Pacify app allows for virtual, 24/7, on-demand access to helpful postpartum resources, including lactation consultants, nutritionists, midwives and social workers. Available in both English and Spanish, the app serves as a critical support at the stage moms need it most. With the onset of the COVID-19 pandemic in early 2020, the ability to access this type of help remotely became even more essential. The Hoag Pacify app is a component of the Women’s Health Institute’s 4th Trimester Program, which was designed to provide comprehensive, personalized support to parents from immediate postpartum through the first year of their baby’s life. THE RESULTS •
By the end of 2021, 6,040 calls were placed by 3,496 patients
•
Enrollment increased by 28% in 2021
•
79% of calls took place outside of regular clinic hours
•
4.9/5 Stars – Average rating (3,940 ratings)
•
Hoag is the first hospital to offer Pacify to every maternity patient at no cost
•
Hoag Innovators’ support for Pacify enabled Hoag to demonstrate proof of concept, functionality and market interest for development of a Hoag-built app—Nona—that offers expanded support for both pregnant women and new moms
PROJECT INVESTMENT UPDATES
Invenio NIO Laser Imaging
INVESTMENT DATE
Fall 2019 INVESTMENT AMOUNT
Reducing Length of Surgery for Patients
$125,000 THE CHALLENGE Pathology examination of specimens removed during surgery can take up to 30 minutes before surgery can continue. Adopting novel pathology and imaging technology can decrease time spent in surgery by minimizing the wait for pathology analysis of the patient’s specimens. THE INNOVATION The NIO pathology and slide imaging system allows examination of specimens from multiple sites in the patient in real time, rather than waiting 30 minutes or more for each sample to be analyzed in the pathology lab. The high quality of the Invenio images allows neurosurgeons to make a more accurate diagnosis in some cases. To maximize the technology even further, Hoag’s team established connectivity to Ambra, a cloud-based image management system, to web stream images directly from the OR to the lab, enabling further streamlining and more rapid diagnosis. The Hoag team also recently activated the system’s artificial intelligence feature, which sends an AI diagnosis via text message to the surgeon within five minutes. THE RESULTS •
Full integration of Invenio NIO laser imaging for central nervous system tumor specimens
•
Average time savings compared with conventional frozen section is 25 minutes
•
Superior diagnostic accuracy helps identify tiny tumors that would otherwise be difficult to detect
•
Completed phase I of a research study to evaluate the clinical feasibility and diagnostic utility of Invenio NIO laser imaging in pancreatic cancer specimens. Phase II of the study is underway
29
LEAF Device System Implementation in Critical Care Units Preventing Pressure Injuries to Critical Care Patients
INVESTMENT DATE
Spring 2019 INVESTMENT AMOUNT
$125,000 THE CHALLENGE Patients endure painful hospital-acquired pressure injuries (HAPIs)— injuries to the skin or underlying tissue from prolonged pressure—when their mobility is limited or when they are unable to change positions in bed. HAPIs can complicate a patient’s recovery, but they can be prevented through timely patient repositioning. THE INNOVATION The LEAF System is an innovative monitoring system that uses a sensor adhered to the patient’s chest to detect their position and movement. The care provider can remotely monitor and reposition the patient at exactly the right time to prevent injuries from prolonged pressure. The LEAF System is currently being used in Hoag’s Critical Care Units (CCUs). THE RESULTS
HOAG INNOVATORS | IMPACT REPORT
•
90% Turn Protocol Adherence (Turn protocol adherence > 85% has been shown to significantly reduce hospital-acquired pressure injuries. Literature shows hospitals without LEAF monitoring have a baseline turn protocol adherence between 38% to 52%.)
•
67% Overall Reduction in Total Hospital-Acquired Pressure Injuries in CCUs
•
57% Overall Reduction in Reportable Hospital-Acquired Pressure Injuries in CCUs
PROJECT INVESTMENT UPDATES
Process Improvement Transitional Care Pilot Program Preventing Hospital Readmissions
139 patients
participated in the Transitional Care Pilot Program
50% reduction
rate of hospital readmission following intervention through the pilot program
INVESTMENT DATE
Fall 2019 INVESTMENT AMOUNT
$100,000 THE CHALLENGE Patients with multiple, complex medical conditions face obstacles in their recovery upon discharge from the inpatient setting. From an inability to follow up with their physician or obtain prescribed medications to difficulty reconciling those new medications with the previous ones to simply not having access to groceries for healthy meals, difficulties can lead to emergency department visits and hospital readmissions. THE INNOVATION Hoag launched the one-year Transitional Care Pilot, funded by the Hoag Innovators, to develop a better way to support these patients. Those enrolled in the pilot receive post-discharge home health care and resource coordination designed to help them navigate their complex medical journey, reduce length of stay and prevent unnecessary hospital readmissions and ER visits. THE RESULTS Now complete, the pilot provided a deeper understanding of what is required to provide effective post-discharge care coordination for medically complex patients. It also served as a proof of concept for successful delivery of acute services in the home setting. This knowledge will be scaled to serve additional patients.
31
HOAG INNOVATORS | IMPACT REPORT
Hoag physicians in every Institute and specialty are on the front line of medical advances through collaborations with leading companies and startups, as well as through their own ideation and creation of processes and techniques that improve patient quality and outcomes. The Innovators are catalyzing progress not only across the Hoag enterprise but in medicine as well. Michael Brant-Zawadzki, MD, FACR Ron & Sandi Simon Executive Medical Director Endowed Chair Pickup Family Neurosciences Institute Senior Physician Executive, Hoag
33
HOAG INNOVATORS | IMPACT REPORT
INNOVATION IN THEIR WORDS
Since it was established in 2017, word of Hoag Innovators and the incredible funding opportunities available have spread throughout Hoag’s clinical community. Physicians and clinical leaders are inspired and excited about the opportunity to partner with Hoag Innovators to bring groundbreaking advances to patient care. Hoag Innovators is also contributing to physician recruitment and retention at Hoag
INNOVATION IN THEIR WORDS
by demonstrating support and an institutional commitment to innovation.
35
Robert Louis, MD, FAANS Empower360 Endowed Chair in Skull Base and Minimally Invasive Neurosurgery, Chief of Neurosurgery, Director of Skull Base and Pituitary Tumor Program, Director of XR Development, Pickup Family Neurosciences Institute Hoag Innovators Funded Project Invenio NIO Laser Imaging Innovation at Hoag means… “Constantly being self-aware and asking how can we do things better, what can we do differently. It’s in Hoag’s DNA to achieve the highest possible outcomes.”
Tara Seery, MD Director of Hepatobiliary Cancer, Co-Director of Cellular Therapy, Hoag Family Cancer Institute Hoag Innovators Funded Project NK Cell Therapy Program
Because of Hoag Innovators… “We have enrolled a high number of late-stage pancreatic cancer patients in the NK (natural killer) cell therapy trial. It’s an unheard-of number for one institution. We’re excited about that because all we want is the best for patients and to give them another chance at continuing to live life. Now, Hoag is constantly being asked by other leading immunotherapy companies to open additional cell therapy trials in other cancer types, which will benefit many more patients."
HOAG INNOVATORS | IMPACT REPORT
INNOVATION IN THEIR WORDS
Allyson Brooks, MD, FACOG Ginny Ueberroth Executive Medical Director Endowed Chair, Women’s Health Institute Hoag Innovators Funded Project Hoag Pacify App
Contributing to health care innovation is important because… “Bringing innovative care to our community is our responsibility and an imperative. At Hoag, we talk a lot about commitment to quality and excellence, but to have those things, you must also be committed to continuous improvement.”
David Liang, MD, PhD Director of Hoag Marfan Syndrome & Related Conditions Program Hoag Innovators Funded Project Hoag Marfan Syndrome & Related Conditions Program
Innovation at Hoag means… “Asking what we can do to take patient care and Hoag to the next level.”
37
HOAG INNOVATORS | IMPACT REPORT
Hoag Innovators is forward-thinking and contributing to a culture of innovation at Hoag—a way of thinking that guides all we do. Their giving is both generous and strategic, positioning our most talented physicians and clinical leaders to nimbly respond to opportunities, test novel and creative approaches to complex problems and, ultimately, transform the health care experience for patients in our community and beyond. Robert T. Braithwaite President and Chief Executive Officer, Hoag
39
For more information, please contact Hoag Hospital Foundation at Hoaginnovators@hoag.org.
